Tasly Pharmaceutical Group Co Ltd (600535) — Cash Flow Reinvestment Rate
Tasly Pharmaceutical Group Co Ltd (600535) has a Cash Flow Reinvestment Rate of 1.06x as of December 2025, reinvesting CN¥587.23 Million (capex CN¥117.78 Million plus investments CN¥-469.45 Million) from operating cash flow of CN¥552.13 Million. Explore Tasly Pharmaceutical Group Co Ltd (600535) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Tasly Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate (2001–2025)
Historical reinvestment intensity for Tasly Pharmaceutical Group Co Ltd across 24 annual periods. Also explore 600535 current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Tasly Pharmaceutical Group Co Ltd (2001–2025)
Year-by-year capital reinvestment analysis for Tasly Pharmaceutical Group Co Ltd. For live market cap and broader valuation context, see Tasly Pharmaceutical Group Co Ltd market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.52x | CN¥746.36 Million | CN¥1.42 Billion | CN¥381.26 Million | ▲ +31.0% |
| 2024 | 0.40x | CN¥805.29 Million | CN¥2.01 Billion | CN¥564.94 Million | ▼ -62.9% |
| 2023 | 1.08x | CN¥2.78 Billion | CN¥2.58 Billion | CN¥668.82 Million | ▲ +86.2% |
| 2022 | 0.58x | CN¥1.32 Billion | CN¥2.29 Billion | CN¥403.45 Million | ▲ +132.4% |
| 2021 | 0.25x | CN¥698.14 Million | CN¥2.80 Billion | CN¥571.73 Million | ▼ -0.4% |
| 2020 | 0.25x | CN¥448.14 Million | CN¥1.79 Billion | CN¥408.81 Million | ▼ -52.4% |
| 2019 | 0.53x | CN¥882.46 Million | CN¥1.68 Billion | CN¥730.78 Million | ▼ -5.5% |
| 2018 | 0.56x | CN¥830.62 Million | CN¥1.49 Billion | CN¥780.10 Million | ▼ -7.3% |
| 2016 | 0.60x | CN¥691.89 Million | CN¥1.15 Billion | CN¥524.68 Million | ▼ -81.7% |
| 2015 | 3.28x | CN¥1.12 Billion | CN¥340.00 Million | CN¥737.84 Million | ▲ +168.1% |
| 2014 | 1.22x | CN¥754.93 Million | CN¥616.76 Million | CN¥754.93 Million | ▼ -36.1% |
| 2013 | 1.92x | CN¥663.56 Million | CN¥346.17 Million | CN¥663.56 Million | ▲ +103.1% |
| 2012 | 0.94x | CN¥390.02 Million | CN¥413.31 Million | CN¥390.02 Million | ▼ -69.8% |
| 2011 | 3.13x | CN¥422.58 Million | CN¥135.14 Million | CN¥422.58 Million | ▲ +643.6% |
| 2010 | 0.42x | CN¥166.13 Million | CN¥395.05 Million | CN¥166.13 Million | ▲ +44.1% |
| 2009 | 0.29x | CN¥116.80 Million | CN¥400.39 Million | CN¥116.80 Million | ▼ -33.7% |
| 2008 | 0.44x | CN¥114.51 Million | CN¥260.21 Million | CN¥114.51 Million | ▼ -51.5% |
| 2007 | 0.91x | CN¥201.23 Million | CN¥221.55 Million | CN¥201.23 Million | ▼ -50.0% |
| 2006 | 1.82x | CN¥255.41 Million | CN¥140.56 Million | CN¥255.41 Million | ▲ +31.8% |
| 2005 | 1.38x | CN¥296.33 Million | CN¥214.90 Million | CN¥296.33 Million | ▼ -24.2% |
| 2004 | 1.82x | CN¥369.62 Million | CN¥203.27 Million | CN¥369.62 Million | ▼ -67.4% |
| 2003 | 5.57x | CN¥328.74 Million | CN¥59.00 Million | CN¥328.74 Million | ▲ +811.2% |
| 2002 | 0.61x | CN¥126.09 Million | CN¥206.22 Million | CN¥126.09 Million | ▼ -57.1% |
| 2001 | 1.42x | CN¥119.35 Million | CN¥83.77 Million | CN¥119.35 Million | — |